News

Keller Rohrback is investigating reports that Wells Fargo charged auto loan borrowers millions of dollars for insurance they did not need.

As the price of EpiPen products continues to sky-rocket, a number of state legislatures have begun to take matters into their own hands.

On July 19, 2017, consumer and reseller dealer plaintiffs filed a Consolidated Class Action Complaint (link to document) in the Northern District of California.

On July 8, 2017 the federal court overseeing the first class action lawsuit filed against Wells Fargo related to unauthorized accounts granted preliminary approval to a $142 million settlement designed to compensate Wells Fargo customers nationwide.

Michael Woerner and a team of attorneys, are investigating cases involving patients who took Invokana, Invokamet, or Invokamet XR and suffered an amputation as a result.

The cases seek to make the care and treatment for Type 1 and Type 2 Diabetes Patients more affordable and increase pricing transparency in the pharmaceutical industry.

Details have come to light about a conspiracy among manufacturers of automobile door locking mechanisms that has had the effect of raising the price of that vital component and hence of any car that includes one of those latches.

Keller Rohrback is investigating the increased risk of leg and foot amputations when taking the SGLT2 inhibitors: Invokana, Invokamet, Invokamet XR for the treatment of type 2 diabetes.

The Joint Panel on Multidistrict Litigation consolidated all of the EcoDiesel cases in courts across the country before Judge Edward M. Chen of the Northern District of California.